Raymond James analyst John Ransom upgraded Aveanna (AVAH) to Outperform from Market Perform with a $9 price target The company reported Q2 results that were well above guidance and consensus forecasts, the analyst tells investors in a research note. The firm sees further deleveraging of Aveanna’s balance sheet as the company’s EBITDA grows and free cash flow is applied to debt reduction. The stock’s current valuation has upside based on the low-double-digit multiples from the higher quality post-acute providers, contends Raymond James.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVAH:
- Aveanna Healthcare Highlights Strong Financial Performance
- Aveanna Healthcare Reports Strong Q2 Growth and Raises 2025 Outlook
- Apple invests extra $100B in U.S., Trump wants Intel CEO to resign: Morning Buzz
- Aveanna Healthcare Reports Strong Q2 2025 Financial Growth
- Aveanna reports Q2 adjusted EPS 18c, consensus 4c